

Translational Prostate Cancer Symposium: Horizons in Prostate Cancer Research

April 24, 2024
Palazzo dei Congressi
Lugano (Switzerland)



Organized by



Institute of Oncology
Research (IOR)



Oncology Institute
of Southern Switzerland (IOSI)

Sponsored by




krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research



Scientific Program

Program times refer to Central European Summer Time (CEST)

8:00-8:50	Registration
8:50-9:00	WELCOME AND OPENING REMARKS Silke Gillesen (Bellinzona, CH), Jean-Philippe Theurillat (Bellinzona, CH)
9:00-10:30	SESSION 1: PROSTATE CANCER PROGRESSION Chair: Howard Soule (Santa Monica, USA) Androgen physiology and regulation of prostate cancer progression Nima Sharifi (Miami, USA) Genomic biomarker-driven neoadjuvant umbrella trial in high-risk localized prostate cancer Martin Gleave (Vancouver, CA) Tumor extrinsic drivers of therapy resistance in prostate cancer Bianca Cali (Bellinzona, CH) The Prostate Cancer Atlas: A tool to interrogate disease progression Jean-Philippe Theurillat (Bellinzona, CH)
10:30-11:00	Coffee Break
11:00-12:30	SESSION 2: LINEAGE PLASTICITY Chair: Clémentine Le Magnen (Basel, CH) Lineage plasticity in prostate cancer: insights and implications Amina Zoubeydi (Vancouver, CA) Decode lineage plasticity in lung cancer: from biology to therapy Triparna Sen (New York, USA) Deciphering single-cell heterogeneity: insights and opportunities Marco Bolis (Milano, IT) Understanding androgen receptor-negative prostate cancer vulnerabilities Phillip Thienger (Bern, CH)
12:30-14:00	Lunch Break
14:00-15:30	SESSION 3: NEW BIOMARKERS AND THERAPEUTIC MODALITIES Chair: Arianna Calcinotto (Bellinzona, CH) Biomarker studies in advanced prostate cancer Johann de Bono (London, UK) Precision metabolic therapy in metastatic prostate cancer Lisa Horvath (Sydney, AU) The role of splicing for survival of lethal prostate cancer Mark A. Rubin (Bern, CH) Co-targeting androgen receptor signaling and resistance mechanisms Daniela Bossi (Bellinzona, CH)
15:30-16:00	Coffee Break
16:00-17:30	SESSION 4: TARGETED PAYLOADS Chair: Howard Scher (New York, USA) Next-generation prostate radioligand therapies and theranostics Ken Herrmann (Essen, DE) Cell surface target dynamics during prostate cancer progression Himisha Beltran (Boston, USA) Targeting Nectin-2 for effective immune therapy in prostate cancer Andrea Alimonti (Bellinzona, CH) Antibody-drug conjugates: are we moving to agnostic development? Giuseppe Curigliano (Milano, IT)
17:30-17:45	CLOSING REMARKS Mark A. Rubin (Bern, CH)
18:00-19:00	Aperitivo Villa Ciani



Attendance to the Symposium counts
0.5 day of animal welfare training and
0.5 ECTS for USI PhD Program.
For certificates, please contact
anna.redaelli@ior.usi.ch